Фармакоэпидемиологический анализ лекарственных средств, используемы при лечении фибрилляции предсердий в реальной клинической практике
Диссертация
Однако, несмотря на выход рекомендаций по терапии ФП, часто назначение антиаритмических препаратов носит эмпирический характер. Это связано с тем, что, с одной стороны, ФП гетерогенное нарушение ритма. Больные резко отличаются друг от друга по частоте, продолжительности приступов и характеру купирования аритмии, наличию органической патологии сердца. А с другой стороны, некоторые антиаритмические… Читать ещё >
Список литературы
- Анализ особенностей фармакотерапии острого инфаркта миокарда с подъемом сегмента 8 Т в стационарах различного типа / Р. М. Магдеев, О. В. Решетько, Е. Ю. Рудниченко и др. // Рациональная Фармакотерапия в Кардиологии — 2011 № 7(6) с. 733−738.
- Арутюнов, Г. Л. Сахарный диабет и атеросклероз: Какова оптимальная стратегия сдерживания атеросклеротического процесса? / Г. Л. Арутюнов // Сердце 2004 — № 1 с. 36−38.
- Бокерия, Л. А. Современная стратегия фармакологического лечения фибрилляции предсердий / Л. А. Бокерия, А. Г. Филатов, Э. Г. Тарашвили //Vанналы Аритмологии -2011 -№ 3-с.5−13. *
- Бокерия, Л. А. Электрофизиологические механизмы фибрилляции предсердий. / Л. А. Бокерия, В. А. Базаев, А. Г. Филатов // Анналы аритмологии № 1, — 2004 — с. 43−49
- Бунин, Ю.А. Комбинированная профилактическая антиаритмическая фармакотерапия фибрилляций и трепетания предсердий / Ю. А. Бунин, Л. Ф. Федякина // РКЖ 2006 — № 6 с.35−45.
- Гиляров, М.Ю. Антитромботическая терапия при фибрилляции предсердий: старые проблемы и новые решения. / М. Ю. Гиляров, В. А. Сулимов // РФК 2010 — № 6(1) — с. 84−88.
- Зырянов, С.К. Фармакоэпидемиология: вчера, сегодня, завтра / С. К. Зырянов // Фарматека.- 2003.- № 3.- с. 13−17.
- Канорский, С.Г. Современная медикаментозная терапия фибрилляции предсердий: выбор тактики, антиаритмических препаратов и схем лечения / С. Г. Канорский // Кардиология 2012 — № 9 — с. 58 — 63.
- Канорский, С.Г. Фибрилляция предсердий у больных с сахарным диабетом 2-го типа: особенности развития и противорецидивной терапии. / С. Г. Канорский, Ю. С. Канорская // Кардиология 2010 — № 7 — с. 31−37.
- Клинические рекомендации ВНОК по диагностике и лечению фибрилляции предсердий / A.JI. Сыркин, В. А. Сулимов, И. Г. Фомина и др. //
- Кардиоваскулярная терапия и профилактика 2005 № 4 (4) приложение 111. t
- Клинические рекомендации ВНОК по диагностике и лечению фибрилляции предсердий / АЛ. Сыркин, В. А. Сулимов, И. Г. Фомина и др. // Кардиоваскулярная терапия и профилактика 2005 — № 4 (4) приложение 111
- Кушаковский, М.С. Аритмии сердца. / М. С. Кушаковский СПб. Изд. ООО «Издательство Фолиант», 2007- - 672 с.
- Недоступ, A.B. Как лечить аритмии. / A.B. Недоступ, О. В. Благова // М: Медпресс-инфо 2007 — с. 303.
- Прикладная фармакоэпидемиология: Учебник / Под ред. В. И. Петрова. -М.: ГЭоТАР-Медиа, 2008. 384 с.
- Рекомендации ВНОК и ВНОА по диагностике и лечению фибрилляции предсердий. / В. А. Сулимов, С. П. Голицын, Е. П. Панченко и др. //
- Рациональная фармакотерапия в кардиологии 2011 — № 7(4) приложение. t
- Сергеев Ю.Д. Юридическое значение первичной медицинскойIдокументации / Ю. Д. Сергеев, Ю. В. Бисюк // Клиническая медицина. 2007. -№ 12. — С. 72−73.
- Страчунский, Л.С. Фармакоэпидемиология: основные понятия и практическое применение / Л. С. Страчунский, С. Н. Козлов, С. А. Рачина // Клиническая фармакология и терапия.- 2001.- Т. 10, — № 4.- С. 35−40.
- Щукин, Ю.В. Факторы риска развития ишемического инсульта у больных с постоянной формой фибрилляции предсердий / Ю. В. Щукин, А. О. Рубаненко, А. В. Германов, О. В. Терешина // Вестник аритмологии 2012 — № 67 — с. 20−25.
- A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. / I.C. Van Gelder, V.E. Hagens, H.A. Bosker, et al. // N Engl j Med 2002 — № 347 — p. 183^1840.
- A novel user-friendly score (HASBLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey / R. Pisters, D. A. Lane, R. Nieuwlaat, et. al. // Chest 2010 № 138 (5), p. 1093−1100.
- A population-based study of mortality among patients with atrial fibrillation or flutter. / H. Vidaillet, J.F. Granada, P.H. Chyou, et. al. // Am J Med 2002 -№ 113-p.365−370.
- A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. / S. Kamath, A.D. Blann, B.S. Chin et al. // Eur Heart J2002'-№ 23 p. 1788−1795.
- ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation. Eur. Heart. J. 2006 — № 27 — p. 1979−2030.
- Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis / R. Marinigh, G. Y. H. Lip, N. Fiotti et. al. // Journal of the American College of Cardiology, 2010 № 56 (11) — p. 827−837.t
- Age-associated changes in electrophysiologic remodeling: a potential contributor to initiation of atrial brillation / E. P. Anyukhovsky, E. A. Sosunov, P. Chandra et al.// Cardiovascular Research 2005 — № 66 (2) — p. 353−363.
- Allessie, M.A. Electrical, contractile and structural remodeling during atrial fibrillation / M.A. Allessie, J. Ausma, U. Schotten // Cardiovas. Res. 2002 -№ 54 -p. 230−246.
- American Heart Association. Tracking women’s awareness of heart disease: an American Heart Association national study. / L. Mosca, A. Ferris, R. Fabunmi et al. // Circulation 2004 — № 109 — p. 573—579.
- Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. / D. Roy, M. Talajic, P. Dorian et al. // N Engl J Med -2000-№ 342-p. 913−920.
- Antiarrhythmic Drug Suppression of Atrial Fibrillation / V. Gerald Naccarelli, Deborah L Wolbrette, K. Mazhar Khan et. al. // US Cardiology 2004 — №-1(1) -p.1−5
- Antiarrhythmic use from 1991 to 2007: Insights from the Canadian Registry of Atrial Fibrillation (CARAFI and II). / J.G. Andrade, S.J. Connolly, P. Dorian et al. // Heart’Rhythm 2010 — № 7 — p. 1171−1177.
- Anticoagulants in heart disease: current status and perspectives. / R. De Caterina, S. Husted, L. Wallentin et al. // Eur Heart J. 2007 — № 28(7) — p.880−913.
- Anticoagulation in atrial fibrillation and flutter. / M.F. Scholten, A.S. Thornton, J.M. Mekel et al. // Europace 2005 — № 7(5) — p. 492−499.
- Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. / M. Gomberg-Maitland, N.K. Wenger, J. Feyzi et. al. // Eur Heart J 2006 — № 27 — p. 1947—1995.
- Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). / J. Hirsh, G. Guyatt, G.W. Albers et al. // Chest 2008 — № 133 — p. 110S-112S.
- Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? / Jay Lin, P.J. Zimetbaum, A. Thosani, et. al. // Am J Med 2010 — № 123 -p.446−453.
- Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation. / Y.J. Chen, S.A. Chen, M.S. Chang, C.I. Lin // Cardiovasc Res 2000 — № 48 — p. 265−273.
- Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks ofmajor cardiovascular diseases and death in the Asia-Pacific region. /The Asia Pacific Cohort Studies Collaboration // Diabetes Care 2003 — № 26 — p.360−366.
- Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). / K. Lakshminarayan, C.A. Solid, A.J.Collins et al. // Stroke 2006 — № 37 — p. 1969−1974.
- Atrial fibrillation and stroke risk prevention in real-life clinical practice / Kok Hoon Tay- Gregory Y. H. Lip- Deirdre A. Lane // Thromb Haemost 2009 — № 101 -p. 415−416.
- Atrial fibrillation as a risk factor for stroke recurrence. // S. Penado, M. Cano, O. Acha et al. // Am J Med 2003 — № 114 — p. 206−210.
- Atrial fibrillation in the 'real world': undecided issues / R. Nieuwlaat, L.W. Eurlings, A. Capucci, H. J.G.M. Crijnsl // Eur Heart J Suppl -2007 № 9 (suppl I) -p. 122−128.
- Atrial fibrillation: a real-life observational study in the Quebec population. / J.R. Guertin, M. Dorais, P. Khairy et. al //Can J Cardiol. 2011 — № 27(6) p. 794−799.
- Atrial fibrillation: a risk factor for increased mortality — an AVID registry analysis. / D.G. Wyse, J.C. Love, Q. Yao et al. H J Interv Card Electrophysiol 2001 — № 5 — p.267—273
- Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. / D.M. Hodgson-Zingman, M.L. Karst, L.V. Zingman, et al. // N Engl J Med 2008 -№ 359 p. 158−165.
- Bednar, M.M. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. / M.M. Bednar, E.P. Harrigan, I.N. Ruskin // Am J Cardiol 2002 — № 89 — p. 1316—13 199.
- Begaud, B. Pharmacoepidemiology: definitions, problems, methodology / B. Begaud, J. Dangoumau // Therapie. 2000. — № 55(1). — P. 113−7.
- Bergman, U. Pharmacoepidemiology from description to quality assessment / U. Bergman // Norwegian Journal of Epidemiology. — 2001. — № 11- P. 31−36.
- Boudina, S. Diabetic cardiomyopathy revisited. / S. Boudina, E.D. Abel // Circulation 2007 № 115 — p. 3213—3223.
- Burashnikov, A, Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. / A. Burashnikov, C. Antzelevitch //Pacing Clin Electrophysiol 2006 — № 29 — p.290 -295.
- Burstein, B. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. / B. Burstein, S. Nattel // J Am Coll Cardiol 2008 № 51 — p.802−809.
- Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. / M. Stramba-Badiale, K.M. Fox, S.G. Priori et al. II Eur Heart J 2006 — № 27 — p. 994—1005.
- Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. (Abstr) / Katritsis D.G., Panagiotakos D.B., Karvouni E. et al. // Am J Cardiol 2003 — № 92 — p. 11 161 119.
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. / S.V. Sorensen, A.R. Kansal, S. Connolly et al. // Thromb Haemost 2011 — № 105 — p. 908−919.
- Di Nisio, M. Direct thrombin inhibitors. / M. Di Nisio, S. Middeldorp, H.R. Buller // N Engl J Med 2005 — № 353 — p. 1028−1040.
- Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. / I. Klem, C. Wehinger, B. Schneider et. al.// Diabetes•v
- Metab Res Rev 2003 — № 19(4) — p.320−328.
- Dronedarone in high-risk permanent atrial fibrillation. / S.J. Connolly, A.J. Camm, J.L. Halperin et al. // N Engl J Med 2011 — № 365 — p.2268 -2276.
- Dulli, D.A. Atrial fibrillation is associated with severe acute ischemic stroke /, H. Stanko, R.L. Levine // Neuroepidemiology 2003 — № 22 p. 118−123.
- Effect of dronedarone on cardiovascular events in atrial fibrillation. / S.H. Hohnloser, H.J. Crijns, M. van Eickels et al. // N Engl J Med -2009 № 360 — p. 668—678.
- Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. / E.M. Hylek, A.S. Go, Y. Chang, et al. // N Engl J Med. 2003 -№ 349-p. 1019−1024.
- Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into he mechanism of the superior efficacy of amiodarone / K. Shinagawa, A. Shiroahita-Takeshita, G. Schram, S. Nattel // Circulation 2003 — № 107- p. 14 401 446.
- Electrical cardioversion for atrial fibrillation: outcomes in «real-life» clinical practice. / C. Berry, S. Stewart, E.M. Payne et. al. // Int J Cardiol. 2001 — № 81(1) -p.29−35.
- Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. / A. Choudhury, I. Chung, A.D. Blann et al. // Chest 2007 -№ 131 — p.809−815.V
- Epidemiology and natural history of atrial fibrillation: clinical implications /4
- S.S. Chugh, J.L. Blackshear, W.K. Shen et al. I I J Am Coll Cardiol. 2001 — № 37 -p. 371−378.
- Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women:2007 Update. / L. Mosca, C.L. Banka, E.J. Benjamin et al. // Circulation 2007 115.p.1481—1501. i
- Falk, R.H. Atrial Fibrillation. / R.H. Falk I I N. Engl J Med 2001-№ 344 -p. 1067−1078.
- Fang, M.C. Atrial fibrillation in the elderly. / M.C. Fang, J. Chen, M.W. Rich // Am J Med 2007 — № 120(6) -p.481−487.
- Gender in atrial fibrillation: ten years later. / H.I. Michelena, B.D. Powell, P.A.
- Brady et. al. // Gend Med 2010 — № 7(3) — p.206−217.
- Global prevalence of diabetes- estimates for year 2000 and projections for 2030. / S. Wild, G. Roglic, A. Green, et. al. // Diabetes Care 2004 № 21 — p. 10 471 053.
- Gowda, R.M. Gender differences in cardiac electrophysiology and arrhythmias. / R.M. Gowda, S.L. P. Wilbur, Schweitzer //Cardiology 2006 — № 15 -p.296—302.
- Hart, R.G. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patierlts Who Have Nonvalvular Atrial Fibrillation. / R.G. Hart, L.A. Pearce, M.I. Aguilar // Ann Intern Med 2007 -№ 146(12) — p. 857 — 867.
- Heart Disease and Stroke Statistics: 2011 Update: A Report From the American Heart Association / L.R. Veronique, S.G. Alan, M.L.-J. Donald et al. // Circulation 2011 — № 123 — p. 18−209.
- Hohnloser, S. H. Benefit-risk assessment of current antiarrhythmic drug therapy of atrial fibrillation / S.H. Hohnloser // Clin Cardiol. 2012 -№ 35, Suppl 1 -p. 28−32.
- Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. / T. Wilke, A. Groth, S. Mueller, et al. // Europace -2013 -№ 15 p.486−493.
- Influence of age, gender, and af recurrence on quality of life outcomes in a population of new-onset af patients: the FRACTAL registry. / M.R. Reynolds, T. Lavelle, V. Essebag et al. // Am Heart J 2006 — № 152 — p. 1097—1103.
- Initiation of atrial fibrillation by ectopic beats originating from the superior >vena cava: electrophysiological characteristics and results of radiofrequency ablation. / C.F.Tsai, C.T. Tai, M.H. Hsieh et. al. // Circulation 2000 — № 102 — p. 67−74.
- International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD) / A. Kakkar, I. Mueller, J. Bassand et al. // American Heart Journal 2012.
- Le’vy, S. Changing epidemiology of atrial fibrillation /Samuel Le’vy // Europace 2013 -№ 15 — p.465−466.
- Lee, C.J. Direct Thrombin Inhibitors. / C.J. Lee, J.E. Ansell // Br J Clin Pharmacol 2011 p. 1365−2125.
- Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons >or =65 years of age (the cardiovascular health study). / J.S. Gottdiener, D.W. Kitzman, G.P. Aurigemma et al. // Am J Cardiol 2006 — №-97 — p.83—89.
- Lenfant, C. Clinical research to clinical practice—Lost in translation? / C. Lenfant // N. Engl. J. Med. 2003. — № 349. — P. 868−874
- Lifetime risk for development of atrial fibrillation: the Framingham Heart Study / Lloyd-Jones DM, T.J. Wang, E.P. Leip, et al. // Circulation 2004 — № 31 110(9)-p. 1042−1046.I
- Lip, G.Y. Identifying patients at risk of stroke despite anticoagulation. / G.Y. Lip, L. Frison, J. Halperin, D. Lane // Stroke 2010.
- Low dose amiodarone and Sotalol in the treatment of recurrent, symptomatic atriai fibrillation: a comparative, placebo controlled study. / G.E. Kochiadakis, N.E. Igoumenidis, M.E. Marketou, et al. // Heart 2000 — № 84 — p. 251−257.
- Maas, A.H.E.M. Red alert for women’s heart: the urgent need for more research and knowledge on cardiovascular disease in women. / A.H.E.M. Maas, Y.T. van der Schouw, V. Regitz-Zagrosek // Eur Heart J 2011 — № 32 — p. 1362—1368.
- Management of Atrial Fibrillation in the Greek Healthcare Setting / Eleftheria Karampli, Kostas Athanasakis, Markos Ollandezos et. al. // J Cardiol 2012 — № 53 -p.273−278.
- Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. / V. Frykman, B. Beerman, L. Ryde’n et al // Eur Heart J -2001 № 22 — p. 1954−1959.
- Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. / W.L. Baker, D.A. Cios, S.D. Sander et al. // J Manag Care Pharm 2009 — № 15(3) — p. 244−252.
- Mice display sex differences in halothane-induced polymorphic ventricular tachycardia. / M.D. Drici, L. Baker, P. Plan et al. //Circulation 2002 — № 106 -p.497—503.
- Mixed treatment comparison of dronedarone, amiodarone, Sotalol, flecainide, and propafenone, for the management of atrial fibrillation. / N. Freemantie, C. Lafuente-Lafuente, S. Mitchell et. al. // Europace 2011 — № 13 — p.329 -345.
- Monogenic atrial fibrillation as pathophysiological paradigms. / S. Mahida, S.A. Lubitz, M. Rienstra, et al. // Cardiovasc. 2011 — № 89(4), p. 692−700.4
- Movahed, M.R. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to over cardiovascular disease. / M.R. Movahed, M. Hashemzadeh, M.M. Jamal // Int J Cardiol 2005 -№ 105 — p. 315—321.
- Naccarelli, Gerald V. Rates and Implications for Hospitalization of Patients >65 Years of Age With Atrial Fibrillation/Flutter / Gerald V. Naccarelli, Stephen S. Johnston, Mehul Dalai // Am J Cardiol 2012 -№ 109 — p.543−549.
- Nattel, S. Atrial electrophysiology and mechanisms of atrial fibrillation. / S. Nattel // J Cardiovasc Pharmacol Ther. 2003 — № 8 — p.5−11.
- Nichols, G.A. Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation. / G.A. Nichols, K. Reinier, S.S. Chugh // Diabetes Care 2009 — № 10 — p. 1851−1856.
- Nieuwlaat, R. Atrial fibrillation management: a prospective survey in ESC Member Countries The Euro Heart Survey on Atrial Fibrillation. / R. Nieuwlaat, A. Capucci, J. Camm // Eur Heart J 2005 — № 26 — p. 2422−2434.
- Olshansky, B. Interrelationships-between the autonomic nervous system and atrial fibrillation. / B. Olshansky // Prog Cardiovasc Dis 2005 — № 48 — p. 57—78.
- Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. / S. Ogawa, T. Yamashita, T. Yamazaki et al. // Circulation 2009 — № 73 — p.242—248.
- Ostgren, C.J. Atrial fibrillation and its association with type 2 diabetes and hypertension in Swedish community. / C.J. Ostgren, J. Merlo, L. Rastam, U. Lindblad // Diabetes Obes Metab 2004 — № 6 — p. 367−374.
- Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. / U. Schotten, S. Verheule, P. Kirchhof, et. ai. // Physiol Rev. 2011 — № 91 — p.265−325.
- Pharmacologic Rate versus Rhythm-Control Strategies in Atrial Fibrillation: An Updated Comprehensive Review and Meta-Analysis / Saurav Chattetjee, M.D., Partha Sardar, M.D., Edgar Lichstein, M. D et. al. // PACE 2013 — № 36 — p. 1 221 333.'
- Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. / J.N. Johnson, D.J. Tester, J. Perry et. al:// Heart Rhythm 2008 — № 5 — p.704−709.
- Recent advances in the molecular pathophysiology of atrial fibrillation. / R.
- Wakili, N. Voigt, S. Kaab, et al. // Clin. Invest. 2011 — № 121(8) — p. 2955−2968. <
- Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. / X. Du, T. Ninomiya, B. de Galan et al. // Eur Heart J 2009 — № 30 — p. 1128—1135.
- Scheinman, M.M. Mechanisms of atrial fibrillation: is a cure at hand? / M.M. Scheinman // Am. Coll. Cardiol. 2000. — №. 35. — p. 1687−1692.
- Secular trends in incidence of atrial fibrillation in Olmstead County
- Minnesota, 1980 to 2000, and implications on the projections for future prevalence. / 1
- Y. Miyasaka, M.E. Barnes, BJ. Gersh, et. al. // Circulation 2006 — № 114 — p. 119— 125.
- Sex-specific increase in the prevalence of atrial fi brillation (The Copenhagen City Heart Study). / J. Friberg, H. Scharling, N. Gadsboll et al. // Am J Cardiol -2003 № 92- p. 1419—1423.
- Steffel, J. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. / J. Steffel, E. Braunwald // Eur Heart J. 2011 № 32(16)-p.: 1968−1976.
- Stramba-Badiale, M. Atrial fibrillation subtypes, risk of stroke, and antithrombotic therapy. / M. Stramba-Badiale // Eur Heart J 2008 — № 29 — p.840— 842.
- Stramba-Badiale, M. Women and research on cardiovascular diseases inv
- Europe: a report from the European Heart Health Strategy (EuroHeart) project. / M. i
- Stramba-Badiale // Eur Heart J 2010 — № 31 -p. 1677—1685.
- Taggar, J.S. Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range. / J.S. Taggar, G.Y. Lip // Curr Med Res Opin -2008 № 24 — p. 1455−1458.
- Temporal relations of atrial fibrillation and congestive heart failure and their joint infl uence on mortality: the Framingham Heart Study. / T.J. Wang, M.G.1.rson, D. Levy, et al. // Circulation 2003 — № 107 — p. 2920−2925.
- The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. / The ACTIVE Investigators // N Engl J Med 2009 — № 360(20)-p. 2066−2078.
- The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. / C. Daly, F. Clemens, J.L. Lopez-Sendon et al. // Eur Heart J 2006 — № 27(11) — p.1298−304. *
- The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. / S. Blech, T. Ebner, E. Ludwig-Schwellinger et al. Drug Metab Dispos 2008 — № 36(2) -p.386−99.
- The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic, and Thrombolytic Therapy. / J. Ansell, J. Hirsh, L. Poller et al. // Chest 2004 — № 126 — p. 204S-233S.
- The RecordAF study: design, baseline data, and profile of patients according to choscn treatment strategy for atrial fibrillation. / J.Y. Le Heuzey, G. Breithardt, J.
- Camm et al. // Am J Cardiol 2010 — № 105 p. 687−693. <
- The Registry of the German Competence NET work on Atrial Fibrillation: patient characteristics and initial management. / M. Nabauer, A. Gerth, T. Limbourg et al. // Europace 2009 — № 11 — p. 423—434.
- Todd, D. M. Repetitive one-month periods of atrial electrical remodeling promote stability of atrial fibrillation / D. M. Todd, A. P. Waiden, S. P. Fynn // Circulation. 2000 — № 102 (Pt. II) — p. 154−155.
- Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities Study / Rachel R. Huxley, Alvaro Alonso, Faye L. Lopez et. al. // Heart 2012 — № 98(2) — p. 133−138.
- Vinik, A.I. Diabetic cardiovascular autonomic neuropathy. / A.I. Vinik, D. Ziegler // Circulation 2007 — № 115 — p.387—397.
- Vinik, A.I. Diabetic cardiovascular autonomic neuropathy. / A.I. Vinik, D. Ziegler //Circulation 2007 — № 115 — p.387—397.
- Waldo, Albert L. Review Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin? / Albert L. Waldo // Cardiovascular Research 200? — № 54 p.217−229.
- Wandell, Per Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study /
- Per Wandell, Axel C. Carlsson, Kristina Sundquist // Eur J Clin Pharmacol 2013 -№ 69 — p. 279−287.V
- Warfarin for the prevention of systemic embolism in patients with non-valvular iatrial fibrillation: a metaanalysis. / L.V. Andersen, P. Vestergaard, P. Deichgraeber et al. // Heart 2008 -№ 94 — p. 1607−1613.
- Watanabe, H. Metabolic Syndrome and Risk of Development of Atrial Fibrillation. The Niigata Preventive Medicine Study. / H. Watanabe, N. Tanabe, T.
- Watanabe, D. Darbar, D.M. Roden // Circulation 2008 -№ 117 — p. 1255−60.
- Watson, T., Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. / T. Watson, E. Shantsila, G.Y. Lip // Lancet 2009 — № 373 — p. 155 166.
- Weitz, J.I. New anticoagulants. / J.I. Weitz, S.M. Bates // J Thromb Haemost -2005 -№ 3 p.1843−1853.
- Wolf, P.A., Atrial fibrillation as an independent risk factor for stroke: the Framingham study / P.A. Wolf, R.D. Abbott, W.B. Kannel // Stroke. 1991 № 22p. 983−988.i
- Women with atrial fibrillation: greater risk, less attention. / A.S. Volgman, M.F.Manankil, D. Mookherjee et al. // Gender Med 2009 — № 6- p. 419−432.
- Zimetbaum P. Antiarrhythmic Drug Therapy for Atrial Fibrillation / P. Zimetbaum // Circulation 2012 -№ 125 — p.381−389.
- Zimetbaum, P. Amiodarone for-Atrial Fibrillation / P. Zimetbaum // N Engl J Med 2007 — № 356 — p. 335−341.